Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018

Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018

PRINCETON, N.J., June 14, 2018 /PRNewswire/ — Taiho Oncology, Inc. and Servier today announced that clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) are being presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain, June 20 to 23. In addition, Taiho

Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)

Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)

June 7, 2018 Taiho’s Patient Assistance Programs Commit to Addressing Patient Burden through New Program Enhancements PRINCETON, N.J., June 7, 2018 /PRNewswire/ — Taiho Oncology, Inc. today announced that, in an effort to further support access for patients and their LONSURF® treatment, the